Sharad D. Iyengar
Research Subjects
Sharad D. Iyengar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ankit Anand
Population Research Centre, Institute for Social and Economic Change, Bengaluru, India
1 shared publication - Birgitta Essén
International Maternal Health, and Migration Unit (IMHm), Uppsala University
1 shared publication - Chandra Sekhar Garudadri
Equitable Healthcare Access Consortium (EHAC), Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad 500034, INDIA
1 shared publication - Dvr Seshadri
Equitable Healthcare Access Consortium (EHAC), Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad 500034, INDIA
1 shared publication - Evita Fernandez
Equitable Healthcare Access Consortium (EHAC), Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad 500034, INDIA
1 shared publication - Jagdish Rattanani
Equitable Healthcare Access Consortium (EHAC), Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad 500034, INDIA
1 shared publication
Latest Publications
- Open Access
- 10 October 2025
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 10 (4) , 343-344
Statement of Concern regarding Corruption in Medical Education
We at Equitable Healthcare Access Consortium (EHAC), a consortium of healthcare organisations and individual practitioners committed to ethical and equitable healthcare in India, wish to express deep concern over the recent First Information Report (FIR) filed by the Central Bureau of Investigation (CBI) [1] and subsequent report that appeared in The Lancet [2]. The FIR implicates officials from the Ministry of Health and Family Welfare, external assessors of the National Medical Commission (NMC), doctors affiliated with private medical colleges, and various intermediaries and administrators.
- 10 October 2025
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 10 (4) , 343-344
Open AccessStatement of Concern regarding Corruption in Medical Education
We at Equitable Healthcare Access Consortium (EHAC), a consortium of healthcare organisations and individual practitioners committed to ethical and equitable healthcare in India, wish to express deep concern over the recent First Information Report (FIR) filed by the Central Bureau of Investigation (CBI) [1] and subsequent report that appeared in The Lancet [2]. The FIR implicates officials from the Ministry of Health and Family Welfare, external assessors of the National Medical Commission (NMC), doctors affiliated with private medical colleges, and various intermediaries and administrators.
- Open Access
- 30 June 2022
- Published by Elsevier in Contraception: X
- Vol. 4, 100079
Observational study of feasibility and acceptability of the levonorgestrel-releasing intrauterine device as a long-acting reversible contraceptive in a primary care setting in India
- 30 June 2022
- Published by Elsevier in Contraception: X
- Vol. 4, 100079
Open AccessObservational study of feasibility and acceptability of the levonorgestrel-releasing intrauterine device as a long-acting reversible contraceptive in a primary care setting in India
- 13 November 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (2) , 173-181
Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial
Introduction: Although home use of misoprostol for early medical abortion is considered to be safe, effective and feasible, it has not become standard service delivery practice. The aim of this study was to compare the efficacy, safety, and acceptability of home use of misoprostol with clinic misoprostol in a low‐resource setting.Material and methods: This was a secondary analysis of a randomized controlled trial conducted in six primary care clinics in India. Women seeking medical abortion within up to nine gestational weeks (n = 731) received mifepristone in the clinic and were allocated either to home or clinic administration of misoprostol. Follow‐up contact was after 10–15 days.Results: Of 731 participants, 73% were from rural areas and 55% had no formal education. Complete abortion rates in the home and clinic misoprostol groups were 94.2 and 94.4%, respectively. The rate of adverse events was similar in both groups (0.3%). A greater proportion of home users (90.2%) said that they would opt for misoprostol at home in the event of a future abortion compared with clinic users (79.7%) who would opt for misoprostol at the clinic in a similar situation (p = 0.0002). Ninety‐six percent women using misoprostol at home or in the clinic were satisfied with their abortion experience.Conclusions: Home‐use of misoprostol for early medical abortion is as effective and acceptable as clinic use, in low resource settings. Women should be offered a choice of this option regardless of distance of their residence from the clinic and communication facilities.
- 13 November 2015
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 95 (2) , 173-181
Home use of misoprostol for early medical abortion in a low resource setting: secondary analysis of a randomized controlled trial
Introduction: Although home use of misoprostol for early medical abortion is considered to be safe, effective and feasible, it has not become standard service delivery practice. The aim of this study was to compare the efficacy, safety, and acceptability of home use of misoprostol with clinic misoprostol in a low‐resource setting.Material and methods: This was a secondary analysis of a randomized controlled trial conducted in six primary care clinics in India. Women seeking medical abortion within up to nine gestational weeks (n = 731) received mifepristone in the clinic and were allocated either to home or clinic administration of misoprostol. Follow‐up contact was after 10–15 days.Results: Of 731 participants, 73% were from rural areas and 55% had no formal education. Complete abortion rates in the home and clinic misoprostol groups were 94.2 and 94.4%, respectively. The rate of adverse events was similar in both groups (0.3%). A greater proportion of home users (90.2%) said that they would opt for misoprostol at home in the event of a future abortion compared with clinic users (79.7%) who would opt for misoprostol at the clinic in a similar situation (p = 0.0002). Ninety‐six percent women using misoprostol at home or in the clinic were satisfied with their abortion experience.Conclusions: Home‐use of misoprostol for early medical abortion is as effective and acceptable as clinic use, in low resource settings. Women should be offered a choice of this option regardless of distance of their residence from the clinic and communication facilities.